Targeted lipidomics distinguishes patient subgroups in mild cognitive impairment (MCI) and late onset Alzheimer's disease (LOAD)

Conclusions These represent the first serum biochemical data to stratify MCI and LOAD patients, advancing efforts to biochemically define patient heterogeneity in cognitive disorders. General Significance Lipidomics offers a new approach for identifying biomarkers and biological targets in cognitive disorders.
Source: BBA Clinical - Category: Biochemistry Source Type: research